Related Experiment Video

Updated: May 9, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer

Stephanie J Malenfant1, Karen R Eckmann, Chad M Barnett

  • 1Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Pharmacotherapy
|August 7, 2013
PubMed

Insights

Pertuzumab offers a new way to treat HER2-positive breast cancer, especially when trastuzumab resistance occurs. Clinical trials show pertuzumab combined with other treatments is effective and well-tolerated.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Trastuzumab is a key targeted therapy for HER2-positive breast cancer.
  • Resistance to trastuzumab is a major clinical challenge.
  • HER2 receptor is a critical target in breast cancer treatment.

Purpose of the Study:

  • To evaluate pertuzumab as a potential therapy to overcome trastuzumab resistance.
  • To assess the efficacy and safety of combining pertuzumab with other treatments.
  • To explore the role of pertuzumab in various stages of HER2-positive breast cancer.

Main Methods:

  • Clinical trials involving patients with HER2-positive breast cancer.
  • Combination therapy studies including pertuzumab, trastuzumab, and chemotherapy (e.g., docetaxel).
  • Evaluation of treatment response and toxicity profiles.

Main Results:

  • Pertuzumab demonstrates potential to overcome trastuzumab resistance.
  • Combination therapies with pertuzumab are effective in metastatic HER2-positive breast cancer.
  • Pertuzumab is well-tolerated with minimal added toxicity.

Conclusions:

  • Pertuzumab is a valuable addition to the treatment of HER2-positive breast cancer, particularly in cases of resistance.
  • Pertuzumab in combination with trastuzumab and docetaxel is a standard of care for newly diagnosed metastatic disease.
  • Ongoing trials will further define pertuzumab's role in early-stage and advanced HER2-positive breast cancer.
Keywords:
HER2breast cancerhuman epidermal growth factor receptorpertuzumab

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...